Literature DB >> 7749137

Detection of c-erbB-2 gene amplification in nipple discharge by means of polymerase chain reaction.

K Motomura1, H Koyama, S Noguchi, H Inaji, C Azuma.   

Abstract

In a patient with non-palpable breast carcinoma, c-erbB-2 gene amplification was detected by means of polymerase chain reaction (PCR) in the small number of breast carcinoma cells present in nipple discharge. Amplification of the c-erbB-2 gene is more frequent in carcinoma in situ than in invasive types. Detection by a PCR-based method may help diagnose non-palpable breast carcinoma with nipple discharge. Since this gene amplification is related to high proliferation, it might provide useful preoperative information regarding intraductal carcinoma of comedo type and predict responses to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7749137     DOI: 10.1007/BF00666075

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  12 in total

1.  Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ.

Authors:  D M Barnes; J S Meyer; J G Gonzalez; W J Gullick; R R Millis
Journal:  Breast Cancer Res Treat       Date:  1991-03       Impact factor: 4.872

2.  Detection of amplified oncogenes by differential polymerase chain reaction.

Authors:  R A Frye; C C Benz; E Liu
Journal:  Oncogene       Date:  1989-09       Impact factor: 9.867

3.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.

Authors:  T Yamamoto; S Ikawa; T Akiyama; K Semba; N Nomura; N Miyajima; T Saito; K Toyoshima
Journal:  Nature       Date:  1986 Jan 16-22       Impact factor: 49.962

4.  HER2/neu amplification and comedo type breast carcinoma.

Authors:  A Borg; F Linell; I Idvall; S Johansson; H Sigurdsson; M Fernö; D Killander
Journal:  Lancet       Date:  1989-06-03       Impact factor: 79.321

5.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

6.  Analysis of gene amplification in archival tissue by differential polymerase chain reaction.

Authors:  A Neubauer; B Neubauer; M He; P Effert; D Iglehart; R A Frye; E Liu
Journal:  Oncogene       Date:  1992-05       Impact factor: 9.867

7.  ErbB-2 protein levels in nipple discharge: role in diagnosis of early breast cancer.

Authors:  H Inaji; H Koyama; K Motomura; S Noguchi; Y Mori; Y Kimura; K Sugano; H Ohkura
Journal:  Tumour Biol       Date:  1993

8.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

Authors:  H B Muss; A D Thor; D A Berry; T Kute; E T Liu; F Koerner; C T Cirrincione; D R Budman; W C Wood; M Barcos
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245

9.  c-erbB-2 expression in benign and malignant breast disease.

Authors:  B A Gusterson; L G Machin; W J Gullick; N M Gibbs; T J Powles; C Elliott; S Ashley; P Monaghan; S Harrison
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

10.  Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.

Authors:  C Wright; S Nicholson; B Angus; J R Sainsbury; J Farndon; J Cairns; A L Harris; C H Horne
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

View more
  2 in total

1.  High levels of DJ-1 protein in nipple fluid of patients with breast cancer.

Authors:  Miki Oda; Masujiro Makita; Keiichi Iwaya; Futoshi Akiyama; Norio Kohno; Benio Tsuchiya; Takuji Iwase; Osamu Matsubara
Journal:  Cancer Sci       Date:  2012-04-04       Impact factor: 6.716

2.  HER2/neu protein expression and fine needle breast aspiration from Argentinean patients with non-palpable breast lesions.

Authors:  Wendy Gabriela Domínguez; Héctor Nardi; Héctor Montero; Esteban Vincent; María Marta Corte; Gabriela Andrea Balogh
Journal:  Exp Ther Med       Date:  2010-07-01       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.